Latest Breaking News On - Large cap stock - Page 1 : vimarsana.com

Investing Options for Roth IRAs from Acorns

The Best Stock ETFs

These exchange-traded funds that invest in stocks earn Morningstar’s top rating in 2023.

How Do I Use Large-Cap Stocks in a Portfolio?

A look at the benefits and risks of these investments, plus our favorite options.

15% upside: Here's why analysts are bullish on this underperforming large-cap stock

Despite its sub-par quarterly earnings result, analysts still see an upside for this FMCG major.

The 5 Biggest Downgrades of 2021

Havells India: Buy Havells India, target price Rs 1198: ICICI Securities

Explore Now ICICI Securities has a buy call on Havells India with a target price of Rs 1198. The current market price of Havells India is Rs 997.35. Havells India Ltd, incorporated in the year 1983, is a Large Cap company with a market cap of Rs 62566.87 Crore, operating in Consumer Durables sector. Havells India's key Products/Revenue Segments include Cables, Electrical Consumer Durables, Others, Domestic Switchgears, Light Fittings & Fixture, Other Operating Revenue, Export Incentives for the year ending 31-Mar-2020. Investment Rationale ICICI Securities models Havells to report PAT CAGR of 17.4 per cent over FY21-FY23E and RoE to be upwards of 20 per cent over FY22-23. It remains positive on the company’s business model due to strong moats and growth opportunities. ICICI Securities maintains a buy rating with a DCF-based target price of Rs 1,198 (implied P/E 52x FY23E).

Shree Cement share price: Buy Shree Cements, target price Rs 32750: Emkay Research

Emkay Research has a buy call on Shree Cements with a target price of Rs 32750 for a time frame of 12 months. The current market price of Shree Cements is Rs 26852.25. Shree Cements Ltd, incorporated in the year 1979, is a Large Cap company with a market cap of Rs 97927.30 Crore, operating in Cement sector. Shree Cements Ltd's key Products/Revenue Segments include Cement, Power, Clinker, Other Operating Revenue and Scrap for the year ending 31-Mar-2020. Investment Rationale Emkay Research maintains its FY22-23 estimates. It has a buy rating with a DCF-derived target price of Rs 32,750 (Jun’22E), implying 19x 1-year forward EV/E. The stock’s premium valuation at current 19.2x EV/E already reflects Emkay's strong outlook on the company, hence it expects the stock’s returns to be driven essentially by earnings compounding. Key downside risk is overseas mergers and acquisition, it added.

Another Quarter of Gains for the U.S. Equity Market

U.S. equity markets finished up in 2021’s first quarter but not without some bumps. The Morningstar US Market Index rose 6.0% for the year through March, with value leading the way for a change. The Morningstar US Small, Mid, and Large Value indexes gained 20.8%, 16.5%, and 9.3%, respectively, through March 31. Growth stocks across the market-cap spectrum, on the other hand, posted losses for the period. High-flying large-growth companies from 2020 faced challenges. Zoom Video Communications (ZM), ServiceNow (NOW), Tesla (TSLA), and MercadoLibre (MELI) each fell in the first quarter, though they still sit miles ahead of their prepandemic levels. The year had a volatile start. The Morningstar US Market Index fell in January as titans gave back 2020 gains. A social-media-fueled frenzy launched GameStop (GME) from about $17 on Jan. 5 to a $348 Jan. 28 peak, squeezing professional investors who had been shorting the moribund retailer. Then good vaccine news, dovish interest-rate signals from Federal Reserve chairman Jerome Powell, and positive economic news lifted stocks for the rest of the quarter.

This large-cap stock gave 245% returns in 11 months

This large-cap stock gave 245% returns in 11 months Vedanta shares have delivered an impressive return of 245 per cent over the last eleven months, from its 52-week low of Rs 60.3 as on March 30, 2020 Chitranjan Kumar | February 22, 2021 | Updated 19:38 IST Vedanta shares hit 52-week of Rs 208.15 on BSE Vedanta share price surged 9 per cent to hit record high of Rs 208.15 on Monday amid report that promoter group is mulling another stake buy in the company. Vedanta shares have delivered an impressive return of 245 per cent over the last eleven months, from its 52-week low of Rs 60.3 as on March 30, 2020. The stock has jumped 12 per cent in the last five days and 26 per cent over one month period. In the calendar year 2021, Vedanta has outperformed the market by rallying 27 per cent, as against a 3.9 per cent gain in the BSE benchmark Sensex. The market capitalisation of Vedanta stands above Rs 75,000 crore.

Pharma Firm Divi's Laboratories, India's Best-Performing Stock, Sees Wave of Optimistic Calls due to the company's capacity-expansion plans

Buy The company's second-quarter earnings topped estimates in early November. Divi's has started building a production facility near Kakinada in India's Andhra Pradesh state, it said in an exchange filing the following month. Overall in absolute terms, analysts' average 12-month target price for Divi's stock has risen about Rs 134 in the past four weeks, the biggest increase among 10 companies on the MSCI India Health Care Index. The stock currently has 17 buy ratings, two holds and three sell recommendations, data compiled by Bloomberg show. "The stock could carry its momentum into this year," said Tushar Manudhane, an analyst at Motilal Oswal Financial Services Ltd. in Mumbai. "They have a good track record of using new capacity efficiently."